Wednesday, April 24, 2024
GenScript Biotech Corporation (GenScript) and Multiply Labs have teamed up to transform the cell therapy manufacturing process. Their partnership focuses on automating the intricate cell isolation phase, a crucial step that currently requires significant manual effort.
Cell isolation using immunomagnetic beads is vital in cell therapy manufacturing but is burdened by complexity and time consumption. The current manual approach involves delicate handling, intricate connections, and meticulous double-checking, all within complex closed-system consumable kits.
The collaboration combines Multiply Labs' robotics expertise with GenScript's GMP-grade CytoSinct 1000 cell isolation solution, capable of isolating up to 120X10^9 total cells within an hour. This partnership aims to introduce the first fully automated solution for bead-based cell isolation, streamlining the process without necessitating substantial modifications to existing manufacturing protocols.
This advancement promises to reduce human error while increasing cell therapy output. With automation handling the labor-intensive tasks, manufacturing personnel can oversee multiple therapies simultaneously, fostering efficiency and scalability in cell therapy production.
Ray Chen, PhD, President of Life Science Group at GenScript, stressed the significance of this collaboration in advancing personalized medicine and expanding the reach of cell therapies. Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs, echoed this sentiment, highlighting the potential for cost reduction and improved patient access to life-changing treatments through automation.
Source: prnewswire.com
